MAGE genes: Prognostic indicators in AL amyloidosis patients.
Yang LiuLei WenLing MaYing KangXin-Xin LiuXiao-Jun HuangGuo-Rui RuanJin LuPublished in: Journal of cellular and molecular medicine (2019)
A high frequency of MAGE-CT (cancer testis) antigens are expressed in Multiple Myeloma (MM) patients; however, in other plasma cell dyscrasias, their potential function remains unclear. We measured the expression of MAGE-CT genes (MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10) in 105 newly diagnosed amyloid light-chain (AL) amyloidosis patients between June 2013 and January 2018 at Peking University People's Hospital using real-time quantitative polymerase chain reaction. In the newly diagnosed AL patients, the positive expression rates of patients with MAGE-C1/CT7, MAGE-C2/CT10 and MAGE-A3 were 83.8% (88/105), 56.71% (38/67) and 22.0% (13/59) respectively. There was no significant correlation between organ propensity and MAGE-CT gene expression. Changes in the MAGE-C1/CT7 levels were consistent with a therapeutic effect. The expression levels of MAGE-C1/CT7, MAGE-C2/CT10 and MAGE-A3 provide potentially effective clinical indicators for auxiliary diagnoses and monitoring treatment efficacy in AL amyloidosis patients.
Keyphrases
- newly diagnosed
- end stage renal disease
- computed tomography
- image quality
- gene expression
- contrast enhanced
- ejection fraction
- chronic kidney disease
- multiple myeloma
- prognostic factors
- magnetic resonance imaging
- peritoneal dialysis
- high frequency
- stem cells
- poor prognosis
- squamous cell carcinoma
- emergency department
- high resolution
- magnetic resonance
- patient reported outcomes
- long non coding rna
- combination therapy
- childhood cancer
- binding protein